# Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

> **NCT00920426** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 9 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1265744 30mg
- **DRUG:** Placebo
- **DRUG:** GSK1265744 5mg

## Key facts

- **NCT ID:** NCT00920426
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-09
- **Primary completion:** 2009-08-13
- **Final completion:** 2009-08-13
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920426, "Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00920426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*